Navigation Links
Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
Date:7/28/2009

SAN FRANCISCO, July 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that it will hold a conference call on Tuesday, August 4, 2009 to discuss the Company's second quarter 2009 results and provide a corporate update. Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, senior vice president and chief financial officer and Robert De Jager, M.D., chief medical officer, will host the call beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). A press release for the second quarter ended June 30, 2009, will be released after markets close on August 4.

To participate in the live call by telephone, please dial 888-515-2880 (United States) or 719-457-2652 (International). In addition, the live conference call is being Webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
2. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
3. Poniard Pharmaceuticals Files Shelf Registration
4. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
5. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
6. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
7. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
8. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
9. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
10. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
11. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK Business ... US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants module ... and biologic sealants used in surgical applications. BioMedGPS estimates the market will grow ...
(Date:10/11/2017)... ... ... wash is a basic first aid supply for any work environment, but most personal eye ... first if a dangerous substance enters both eyes? It’s one less decision, and likely quicker ... eye piece. , “Whether its dirt and debris, or an acid or alkali, getting anything ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... Philadelphia, PA (PRWEB) , ... October 10, 2017 ... ... University City Science Center’s FirstHand program has won a US2020 STEM Mentoring Award. ... accept the award for Excellence in Volunteer Experience from US2020. , US2020’s mission ...
Breaking Biology Technology:
(Date:6/30/2017)... Va. , June 30, 2017 ... leading developer and supplier of face and eye ... ATA Featured Product provider program. ... an innovative way to monitor a driver,s attentiveness ... greatly from being able to detect fatigue and ...
(Date:5/16/2017)... 16, 2017  Veratad Technologies, LLC ( www.veratad.com ), ... and identity verification solutions, announced today they will participate ... May 15 thru May 17, 2017, in ... Trade Center. Identity impacts the lives ... today,s quickly evolving digital world, defining identity is critical ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
Breaking Biology News(10 mins):